工程玉米面粉与脂肪酸:结构修改和糖尿病管理的影响
Yumeng Yang1,2,3, Songyi Lin1,2,3,4, Xinqi Du1,2,3
1SKL of Marine Food Processing & Safety Control, Dalian Polytechnic University, Dalian, 116034, PR China. tytgm126@163.com.
Food & function
|June 4, 2025
概括
用酸 (SO) 修改性玉米面粉 (WC) 从物理上降低了粉的消化能力和葡萄糖指数. 这种功能性食品成分,WCO,改善了小鼠的II型糖尿病症状和肠道微生物群.
科学领域:
- 食品科学 食品科学 食品科学
- 营养科学 营养科学
- 生物化学 生物化学
背景情况:
- 粉的消化能力和血糖指数显著影响代谢健康和糖尿病管理.
- 开发新的策略来调节粉特性对于功能性食品的开发至关重要.
研究的目的:
- 通过使用脂肪酸 (NaFAs) 来研究玉米面粉 (WC) 的物理修饰,以降低其消化能力和葡萄糖指数.
- 阐明在NaFA修改后WC的结构变化及其对消化特性的影响.
- 在小鼠模型中评估改性WC对II型糖尿病症状和肠道微生物群的生理影响.
主要方法:
- 合成具有不同NaFA碳链长度的WC-NaFA复合物.
- 结构性质的表征 (复杂度指数,分支程度) 和修改后的WC的消化性.
- 在体内评估用油酸盐 (WCO) 修改的WC对低血糖和肠道微生物群调节作用. 在链毒素诱导的糖尿病小鼠中.
主要成果:
- 酸 (C18) 的结合导致了通过键和疏水力在WC中形成复杂的B+V型结构.
- WC修改使复杂度指数增加了24.28%,分支程度增加了12.03%,使消化能力从83.66%降低到47.48%.
- 世界卫生组织显著改善了II型糖尿病症状,包括降低血糖,提高葡萄糖耐受性和减少炎症,同时促进有益的肠道细菌.
结论:
- 用油酸盐对玉米面粉进行物理修改是一种有效的策略,可以降低粉的消化能力和血糖指数.
- 通过低血糖和肠道微生物群调节作用,WCO显示出作为一种功能性食品成分,用于管理和预防II型糖尿病的潜力.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Overview of Carbohydrate Metabolism
2.0K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
2.0K
Diabetes: Symptoms, Diagnosis, and Complications
715
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
715
Diabetes: Management and Pharmacotherapy
412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278


